Background-In giant cell arteritis (GCA), vasculitic damage of the aorta and its branches is combined with a syndrome of intense systemic inflammation. Therapeutically, glucocorticoids remain the gold standard because they promptly and effectively suppress acute manifestations; however, they fail to eradicate vessel wall infiltrates. The effects of glucocorticoids on the systemic and vascular components of GCA are not understood. Methods and Results-The immunoprofile of untreated and glucocorticoid-treated GCA was examined in peripheral blood and temporal artery biopsies with protein quantification assays, flow cytometry, quantitative real-time polymerase chain reaction, and immunohistochemistry. Plasma interferon-␥ and interleukin (IL)-17 and frequencies of interferon-␥producing and IL-17-producing T cells were markedly elevated before therapy. Glucocorticoid treatment suppressed the Th17 but not the Th1 arm in the blood and the vascular lesions. Analysis of monocytes/macrophages in the circulation and in temporal arteries revealed glucocorticoid-mediated suppression of Th17-promoting cytokines (IL-1␤, IL-6, and IL-23) but sparing of Th1-promoting cytokines (IL-12). In human artery-severe combined immunodeficiency mouse chimeras, in which patient-derived T cells cause inflammation of engrafted human temporal arteries, glucocorticoids were similarly selective in inhibiting Th17 cells and leaving Th1 cells unaffected.
ever, benefits of pulse glucocorticoids were delayed until 12 to 18 months into treatment. 6 Acetylsalicylic acid has a role as adjuvant therapy, partially by inhibiting inflammation and partially through antiplatelet effects. 7, 8 Steroid withdrawal after Ͼ2 years of therapy is often accompanied by recurrence of inflammatory markers, and vascular inflammation persists despite glucocorticoid treatment. 9 -11 In essence, despite their prompt, impressive therapeutic effects, glucocorticoids fail to abrogate vasculitis. Improved disease management and avoidance of severe glucocorticoid side effects will require a better understanding of underlying immune abnormalities.
Both the innate and adaptive immune system contribute to GCA pathogenesis. 12 Granulomatous inflammatory infiltrates composed of CD4 T cells, activated macrophages, and multinucleated giant cells induce intimal hyperplasia and luminal compromise. 13 In cell-depletion studies, dendritic cells (DCs) have emerged as the predominant antigen-presenting cell. 14, 15 DCs are now recognized as an indigenous cell population in human macrovessels, where they have important surveillance functions and sense pathogen-derived motifs. 16, 17 The nature of T cells driving GCA and the manner in which they are affected by immunosuppression are unresolved. The finding of identical T cells in the right and left temporal artery has strongly supported antigen as an instigator. 18 Functional selection and mechanisms of action of wall-infiltrating T cells remain to be elucidated. Interferon (IFN)-␥ is a dominant cytokine in the arteries, whereas Th2-derived cytokines are consistently absent. 19, 20 Whether interleukin (IL)-17-producing Th17 cells have a role in GCA is unknown.
GCA is a treatable yet incurable disease. In the present study, we have made use of the therapeutic effects of glucocorticoids to decipher which immunopathways maintain systemic and vascular inflammation. By studying patients before and after initiation of glucocorticoids, immune abnormalities responsive to this immunosuppressive treatment could be dissected from those resistant to glucocorticoids. Glucocorticoids inhibit the production of cytokines that promote and sustain CD4 T-cell differentiation into Th17 cells. Conversely, cytokines regulating the differentiation of Th1 cells and Th1 responses persist even in chronically treated patients. Differential susceptibility of Th1 and Th17 cells to steroid-mediated suppression provides important pathogenic clues and encourages the development of therapeutic strategies that can disrupt both arms of vasculitic T-cell responses.
Methods

Study Cohorts
Demographic and clinical characteristics of patients and controls enrolled into this study are listed in Table I in the online-only Data Supplement. Eleven patients donated samples for studies before therapy was initiated and were reexamined on steroid therapy. In addition, 15 patients were tested only before therapy initiation, and 23 patients were recruited while they were already on therapy. Thirty-four healthy volunteers aged 61 to 80 years served as controls. The age distribution of patients and controls was not significantly different ( Table I in the online-only Data Supplement). Prior or current diagnosis of cancer, autoimmune disease other than GCA, or chronic infection was an exclusion criterion. Emory University and the Mayo Clinic review boards approved the protocol, and all donors gave informed consent.
Glucocorticoid Treatment
Patients with a positive temporal artery biopsy started on prednisone 60 mg daily. Patients were monitored monthly for clinical signs of disease, and glucocorticoid was tapered by 10% every 2 weeks. Adjustment of glucocorticoid therapy was left to the decision of the treating physician and was based on clinical and laboratory findings.
Reagents and Antibodies
Reagents and antibodies are listed in Table II in the online-only Data Supplement.
Cell Preparation, Culture, and Flow Cytometry
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors and GCA patients. After 4-hour stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin in the presence of brefeldin A, cells were stained with anti-CD3 (PE), anti-CD4 (PerCP), anti-IFN-␥ (FITC), and anti-IL-17 (APC) antibodies, or, alternatively, they were stained with anti-CD3 (FITC) and anti-Foxp3 (PE). Flow cytometry was performed on an LSR II (BD Biosciences, San Jose, Calif), and data were analyzed with FlowJo 7.2.2 software. Naive CD4 T cells and CD14 ϩ monocytes were purified as described 16 and cocultured at a 2:1 ratio for 4 days with lipopolysaccharide, anti-CD3, and anti-IL-1␤, anti-IL-6, or anti-IL-23p19 neutralizing antibodies. Relevant antibody isotype served as control. For enrichment of Th17 cells, CD45RO ϩ memory CD4 T cells were isolated from PBMCs and cocultured with CD14 ϩ monocytes (2:1) for 7 days with lipopolysaccharide (1 g/mL), anti-CD3 (1 g/mL), anti-human IFN-␥ (2 g/mL), and anti-human IL-4 (2 g/mL) antibodies. Accumulation of Th17 and Th1 cells in such T-cell lines was monitored by flow cytometry.
Quantitative Real-Time Polymerase Chain Reaction
Total RNA was isolated from human tissues and cells. IL-17, IFN-␥, Foxp3, IL-1␤, IL-6, IL-23p19, IL-12p35, IL-12p40, matrix metalloproteinase-9, and ␤-actin gene transcripts were quantified by real-time polymerase chain reaction (PCR) and adjusted to 2ϫ10 5 copies of the housekeeping gene ␤-actin as described. 10, 16, 17 Primer sequences and PCR conditions are listed in Table III in the online-only Data Supplement.
ELISArray
Plasma cytokine levels (IL-1␤, IL-6, IL-12, IL-17, IFN-␥) were analyzed with Human Autoimmune Response Multi-Analyte ELISArray kits (SABiosciences Corp, Frederick, Md). Plasma samples (1:2 dilutions) were incubated in 96-well plates precoated with individual cytokine capture antibodies for 2 hours. After they were washed, biotin-conjugated cytokine detection antibodies were added for 30 minutes. Bound antibodies were detected with avidin-HRP and development solution. Color reactions were quantified at OD 450.
Immunohistochemical Staining
Sections of paraffin-embedded arteries were processed and stained with anti-CD3, anti-CD4, anti-CD8, anti-CD14, anti-CD15, anti-IL-17, or anti-IFN-␥ antibodies as described. 16, [21] [22] [23] [24] Purified mouse or rabbit IgG control antibodies were used instead of the primary antibody as a control.
Human Temporal Artery-Severe Combined Immunodeficiency Mouse Chimeras
Human temporal artery-severe combined immunodeficiency (SCID) mouse chimeras were generated as described previously. 16 -17 Mice implanted with artery tissues from the same donor were assigned to either of 2 treatment arms (dexamethasone or vehicle) and a control arm (noninflamed artery). At day 7 after implantation, mice were injected intraperitoneally with lipopolysaccharide (3 g per mouse) or PBS (control arm). On day 8, T-cell lines enriched for Th17 cells (10 7 cells per mouse) were adoptively transferred into the chimeras intravenously. On day 9, chimeras were treated with dexamethasone (4 mg/kg; Sigma-Aldrich, St Louis, Mo) as described. 11 Fifteen days after implantation, arterial grafts were harvested for RNA extraction or OCT embedded for immunostaining. The protocol was approved by the Emory University Institutional Animal Care and Use Committee.
Data Analysis
A detailed description of the statistical tools and study cohorts is given in Statistical Methods and Table IV in the online-only Data Supplement. Analysis of data in Figure 1 required the development of a customized approach because some patients were tested only before treatment, some were tested only while on treatment, and some patients were tested twice, before initiation of glucocorticoid and while on glucocorticoid. Analysis of data sets in Figures 2, 3, 4, and 5 involved 1-sample t or Wilcoxon test, 2-sample t or Wilcoxon test, or Behrens-Fisher-Welch testing, as appropriate. Friedman rank sum test was applied to compare results from antibody blocking assays with anti-IL-1␤, anti-IL-6, and anti-IL-23. PϽ0.05 was considered significant. Data are presented as meanϮSEM.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agreed to the manuscript as written.
Results
Circulating Th1 and Th17 Cells Are Markedly Expanded in GCA and Are Differentially Affected by Glucocorticoid Therapy
To identify functionally relevant T-cell subsets in GCA, frequencies of IL-17-producing Th17 and IFN-␥-producing Th1 and Foxp3 ϩ regulatory CD4 T cells were compared in patients with untreated GCA (nϭ26) and age-matched healthy controls (nϭ34). In GCA patients, frequencies of circulating Th17 cells among CD4 T cells were expanded 8-fold, ranging from 1.1% to 5.3% and averaging 2.2% ( Figure 1A ). In healthy controls, only 0.03% to 0.59% of T cells produced IL-17 ( Figure 1A ). Th1 cells accounted for 20.6% of CD4 T cells in GCA patients in contrast to only 11.8% in controls ( Figure 1B ). The patients also carried a population of IL-17 ϩ IFN-␥ ϩ double-positive cells ( Figure  1E ), which were essentially lacking in controls ( Figure 1D ). Frequencies of CD4 Foxp3 ϩ Treg were indistinguishable in patients and controls ( Figure 1C and Figure I in the onlineonly Data Supplement). In essence, untreated GCA was associated with a marked expansion of IFN-␥-and IL-17producing T-cell subsets.
To explore the effect of glucocorticoid therapy on cytokine-producing T-cell subsets, frequencies of circulating Th1 and Th17 cells were measured in steroid-treated patients (nϭ34) who were on an average dose of 16.7 mg of prednisone daily. All patients initially received prednisone at 60 mg/d with continuous dose reduction by 10% every 2 weeks, unless the patients had recurrence of vasculitic symptoms. Glucocorticoid therapy markedly suppressed circulating Th17 cells, normalizing the average frequencies to 0.46% of CD4 T cells ( Figure 1A ). In treated patients, Th17 frequencies were indistinguishable from those in control donors (range, 0.11% to 0.89%) (Pϭ0.101). Glucocorticoid also ablated the IL-17 ϩ IFN-␥ ϩ double-positive cells ( Figure  1F ). However, glucocorticoid essentially left unaffected frequencies of Th1 cells ( Figure 1B and 1F) , with a mean of 20.2% and 18.4% before and after therapy, respectively. In addition, frequencies of Foxp3 ϩ Treg were unaltered by glucocorticoid therapy ( Figure 1C and Figure I in the onlineonly Data Supplement). In essence, in steroid-treated patients, Th17 frequencies returned to normal, whereas the expansion of Th1 cells persisted.
Measurement of circulating IL-17 and IFN-␥ protein confirmed elevation of both inflammatory cytokines before glucocorticoid therapy and effective suppression of IL-17 but not IFN-␥ in treated patients ( Figure 1G and 1H) .
To assess the time frame of glucocorticoid-mediated suppression of Th17 cells and understand whether Th17 cells rebound once steroid doses were tapered, 11 patients were examined before the initiation of prednisone therapy and reexamined at different time points while on steroids (Table;  Table V in the online-only Data Supplement). Treatment for 10 weeks was sufficient to bring Th17 frequencies into the normal range. With decreasing steroid doses, the suppressive effect was maintained and was still observed after treatment for 9 months. There was no evidence that tapering steroids below 10 mg/d resulted in a rebound of Th17 cells.
Glucocorticoid Therapy Selectively Suppresses IL-17-Producing Cells and Spares IFN-␥-Secreting Cells in Vasculitic Lesions
Temporal artery samples with typical changes of GCA were collected from 8 untreated patients, and the second-side biopsy was obtained after 3 to 9 months of glucocorticoid therapy. All second-side biopsies examined in this study were read positive for vasculitis by histomorphology. Temporal artery specimens free of GCA served as controls. Extracts from the tissue samples were analyzed for the expression of IL-17, IFN-␥, and Foxp3-specific sequences by real-time PCR, and IL-17-and IFN-␥-producing cells were identified by immunohistochemical staining of tissue sections. The control samples were essentially negative for IL-17, IFN-␥, and Foxp3 transcripts, and no cells staining positive for IL-17 or IFN-␥ were detected. The samples from untreated patients expressed high transcript levels for IL-17, IFN-␥, and Foxp3 (Figure 2A to 2C) . Glucocorticoid therapy resulted in marked suppression of IL-17 production (Figure 2A) . In contrast, In the temporal arteries of untreated GCA patients, immunostaining for CD3 localized tissue-infiltrating T cells in all wall layers, with preferential clustering in the medial smooth muscle layer ( Figure 2E ). IL-17-producing cells were abundant ( Figure 2F ) and followed the distribution pattern of CD3 ϩ T cells ( Figure 2F and 2G ). IL-17 ϩ cells were also found around adventitial vasa vasorum and diffusely spread through the hyperplastic intima. Mean numbers of IL-17producing cells reached 36 per high-powered field ( Figure  2D ). Almost all lymphocytic cells in the vessel wall infiltrates are CD4 ϩ , with only very few CD8 T cells represented, assigning IL-17 production mostly to CD4 T cells ( Figure II in the online-only Data Supplement). IFN-␥-producing cells were represented among all wall-infiltrating T cells but displayed a preference for the adventitial layer. In arteries harvested from treated patients, the infiltrates continued to include abundant IFN-␥-producing cells ( Figure 2I) , mainly in the inner adventitia. However, only few cells stained positive for IL-17, and the intensity of staining was reduced ( Figure 2H ), suggesting reduced production by individual cells.
Glucocorticoids Inhibit Th17-Promoting Cytokines in Peripheral Monocytes and in Vasculitic Lesions
T-cell differentiation into either Th1 or Th17 cells is directed by the cytokine environment that is shaped by antigen-pres-enting cells, such as DCs and monocytes/macrophages. IL-1␤, IL-6, and IL-23 contribute to Th17 differentiation; IL-12 supports the development of Th1 cells. 25 To quantify the contribution of different cytokines to the expansion of Th17 cells in GCA, naive CD4 T cells were cocultured with autologous CD14 ϩ monocytes in the presence of neutralizing antibodies against IL-1␤, IL-6, or IL-23. Monocytes from GCA patients effectively drove Th17 and Th1 differentiation ( Figure III in the online-only Data Supplement). Th17 differentiation was suppressed by anti-IL-1␤, anti-IL-6, and anti-IL-23, implicating all 3 cytokines in the process. Blocking IL-1␤ or IL-6 had no effect on the development of Th1 cells. Removing IL-23 activity, however, enhanced the outgrowth of Th1 cells markedly. The data assigned a critical role to IL-1␤, IL-6, and IL-23 in promoting the shift toward Th17 cells in GCA.
To understand whether glucocorticoid functions by targeting Th1-and Th17-promoting cytokines, we analyzed protein levels in the plasma and gene expression in circulating monocytes and temporal artery tissue samples. Protein concentrations of circulating IL-1␤, IL-6, and IL-12 were elevated significantly in untreated patients ( Figure 3A to 3C) . In response to therapy, IL-1␤ and IL-6 were markedly reduced ( Figure 3A and 3B) , but IL-12 remained unaffected ( Figure  3C ). In circulating monocytes, transcript levels for IL-1␤, IL-6, IL-12p35, IL-12p40, and IL-23p19 were all increased in GCA patients compared with healthy individuals (Figure 3D to 3H). On glucocorticoid therapy, IL-1␤ and IL-6 gene expression levels in GCA monocytes were completely inhib- ited ( Figure 3D and 3E) . IL-23p19 gene expression was suppressed by 52% in CD14 ϩ monocytes from treated patients ( Figure 3F ). The treatment did not affect IL-12 gene expression ( Figure 3G and 3H) . A similar pattern emerged for the tissue expression of Th17-and Th1-promoting cytokines. In untreated cases, IL-1␤, IL-6, IL-23p19, IL-12p40, and IL-12p35 gene expression levels were markedly upregulated ( Figure 4A to 4E) . Glucocorticoid treatment resulted in suppression of IL-1␤, IL-6, and IL-23p19 transcription (Fig-ure 4A to 4C ), but production of IL-12p35 and IL-12p40 transcripts was maintained in the arteries (Figure 4D and 4E ).
Glucocorticoid Selectively Inhibits Recruitment and Survival of Th17 Cells in Vessel Wall Inflammation in Human Artery-SCID Mouse Chimeras
To verify the differential effects of corticosteroid treatment on the accumulation of T-cell effectors in vasculitic lesions, T-cell lines generated from GCA patients were adoptively transferred into artery-SCID chimeras engrafted with human temporal arteries ( Figure 5 ). Expanded T-cell lines contained a high frequency of Th17 cells as well as Th17/Th1 cells, confirming a bias toward the induction of the Th17 lineage ( Figure 5A ). Under similar conditions, T-cell cultures from healthy controls yielded Ͻ2% Th17 cells (data not shown). After injection of the patient-derived T-cell lines, Th17 as well as Th1 cells accumulated in the arteries, as evidenced by the levels of IL-17-and IFN-␥-specific sequences ( Figure   Figure 5 . Dexamethasone prevents Th17-but not Th1-mediated vessel wall inflammation in human artery-SCID chimeras. Normal human arteries were engrafted into SCID mice. One week later, mice were injected with lipopolysaccharide or saline as control (Con). Twenty-four hours later, T-cell lines established from the blood of GCA patients were adoptively transferred (10 7 cells per mouse). Chimeras were treated with either dexamethasone (4 mg/kg) (Tx) or saline (No Tx), and temporal arteries were explanted. T-cell lines from the GCA patients had similar proportions of Th17, Th1, and Th17/Th1 cells; a representative cytometric dot plot is shown (A). Tissue extracts from explanted arteries were analyzed for IL-17 (B) and IFN-␥ (C) by quantitative real-time PCR. Data are presented as meanϮSEM from 3 independent experiments. Tissue sections from explanted arteries were stained with anti-IL-17 antibodies (D to F). IL-17 ϩ T cells (dark brown) were quantified in a minimum of 12 high-powered fields (HPF) for each arterial cross section (G). Transcript levels of IL-6 (H) and matrix metalloproteinase (MMP)-9 (I) in the implants were measured by quantitative real-time PCR as well. Magnification ϫ600 in D, E, and F. 5B and 5C). Treatment with dexamethasone (4 mg/kg) inhibited accumulation of IL-17 messenger RNA but did not affect production of IFN-␥. Immunohistochemical analysis confirmed dense infiltrates of IL-17 ϩ cells in the arteries from untreated chimeras ( Figure 5E and 5G) . Conversely, after corticosteroid therapy, the density of IL-17 ϩ cells in the vessel wall was markedly diminished (Figure 5F and 5G) . Reduction in the frequency of wall-infiltrating IL-17 ϩ cells was associated with significantly lower levels of IL-6 sequences ( Figure 5H ). In addition, matrix metalloproteinase-9 transcript levels, a marker for tissue-destructive macrophages, declined, suggesting that preventing the infiltration/ survival of IL-17 cells in the infiltrates may have tissueprotective effects ( Figure 5I ). In essence, glucocorticoids selectively regulate the composition of the inflammatory T-cell infiltrate; Th17 cells are highly sensitive to the inhibitory effects, whereas the recruitment and enrichment of Th1 cells and their cytokine-producing functions are unaffected.
Discussion
Glucocorticoids are highly effective in treating the constitutional symptoms of GCA, including myalgias, malaise, fever, anorexia, and headaches. However, most patients require therapy for years to avoid disease flares, suggesting only partial responsiveness to this immunosuppressive approach.
In the present study, we report that glucocorticoids act by selectively suppressing Th17 responses in the vasculitic lesions and in the periphery, whereas Th1 responses are spared. The anti-inflammatory actions of glucocorticoid result from modulation of monocytes/macrophages; Th17promoting cytokines decline markedly, and the Th1promoting IL-12 continues to be produced. In essence, glucocorticoids effectively treat the acute manifestations of GCA, which appears to be closely associated with excessive production of Th17-promoting cytokines by innate immune cells and IL-17 by T cells. Glucocorticoids fail to abrogate vasculitis because Th1-driving cytokines and Th1 cells are refractory to glucocorticoid-mediated suppression. To reset immune abnormalities in GCA, glucocorticoid must be combined with additional therapies. GCA is considered a prototypical steroid-responsive disease. Patients have fast and profound improvement of constitutional symptoms, such as malaise, anorexia, fevers, and myalgias. Steroids are believed to be vision protective, and headaches and scalp tenderness often respond promptly. 26 -28 However, vascular lesions persist, and disease flares are frequent on tapering of glucocorticoids.
The present study has made use of comparing abnormalities in the innate and adaptive immune system before and after therapy. T cells and macrophages are critical players in the vasculitic process sustaining the granulomatous inflammation in the arteries. 22, 29 Highly activated macrophages not only occupy the wall infiltrates but also circulate in the blood. 30 -32 High levels of IL-6 have been associated with disease activity and therapeutic response. 11, 33 Besides IL-6, circulating IL-1␤ and IL-12 proteins were elevated in untreated patients ( Figure 3A to 3C) . The cytokine production pattern found in the vasculitic lesions is essentially identical to that detected in circulating monocytes. On the side of the adaptive immune system, GCA patients have marked expansions of Th1 and Th17 cells. Th1 and Th17 cells are now considered to drive 2 distinct inflammatory pathways. 34 -36 Only 1 of these pathways in GCA is amendable to glucocorticoid-mediated suppression in both patients and mouse chimeras. GCA patients utilize IL-1␤, IL-6, and IL-23 to induce Th17 cells, and these cytokines are effectively suppressed by glucocorticoids. From these data, it appears that the patients' immune defects originate in the innate immune system, where excessive amounts of IL-1␤, IL-6, and IL-23 are produced. Multiple cell populations, including DCs, monocytes, and macrophages, are the main sources of IL-1␤, IL-6, and IL-23. The present study assigns a top position to these cells in the pathogenic events leading to GCA, supporting the disease model in which vessel wallresiding DCs have checkpoint function and are the first to respond to disease-inducing danger signals. 16, 17 Th17 cells have been linked to a number of autoimmune diseases, 37 cardiac allograft rejection, and vasculopathy. 38 How IL-17 facilitates vascular tissue damage is less well understood, but IL-17 receptors are expressed on fibroblasts, endothelial cells, and vascular smooth muscle cells, all instrumental in the arterial wall structure (data not shown). With 8-fold enrichment of Th17 cells in the blood, IL-17 may even have a role in the typical myalgias and muscle stiffness associated with GCA.
A model system in which vessel wall inflammation can be induced in normal human arteries allowed analysis of some of the mechanisms related to Th1-and Th17-mediated disease. T-cell lines from GCA patients were tested for their inflammation-inducing capacity. T-cell subset analysis revealed a strong bias toward the enrichment of Th17 and Th17/Th1 cells. In normal donors, Th17 cells account for only a minor fraction of effector T cells. Conversely, T-cell lines expanded from GCA patients fell into 3 equally proportioned subsets: Th1 cells, Th17 cells, and Th1/Th17 cells. Whether the expansion of Th17 cells is solely a consequence of disturbed innate immune function, producing excess amounts of Th17-promoting cytokines, or whether the patients also have restructuring of the T-cell repertoire needs to be addressed in further studies.
Corticosteroids essentially depleted Th17 cells from the lesions either by inhibiting recruitment or by jeopardizing survival in the vessel wall environment. Recent data suggest that tissue invasion of human arteries is a feature of CCR6 ϩ T cells. 16 The CCR6 receptor is typically found on Th17 cells (data not shown). CCL20, the ligand for CCR6, has been implicated in facilitating selective recruitment of T cells, causing panarteritis as opposed to a periarteritic architecture of the vascular infiltrates. 16 After dexamethasone treatment, Th1 cells continued to infiltrate the wall, recapitulating findings in the arteries from the treated patients.
The present study has multiple implications for our understanding of GCA pathogenesis and management. The data suggest that at least 2 arms of the adaptive immune system contribute to GCA. Th17 immunity seems to be more important for acute manifestations, both systemically and in the blood vessels; Th1 immunity is associated with chronically persistent vascular lesions. From a mechanistic point of view, the ability to suppress IL-1␤, IL-6, and IL-23 while IL-12 production is essentially unaffected suggests that 2 different types of antigen-presenting cells or 2 different danger signals may promote T-cell differentiation in GCA. It is important to realize, however, that the approach taken in this study, analyzing the different blood and tissue cytokines as dependent parameters, does not entirely reflect the complex and interrelated biology of the disease, yet this is the only approach currently available.
The potency of glucocorticoids to normalize proinflammatory Th17 cells is consistent with the clinical experience that this therapy is prompt and effective. In most patients, constitutional symptoms (myalgias, fever, malaise, anorexia) and signs of vascular inflammation (headaches, temporal tenderness) are markedly improved. However, vessel wall infiltrates, and thus continuous wall damage, can persist over extended periods. The resistance of circulating and tissue Th1 cells indicates partial response, even on high doses of glucocorticoids. 9, 10 Current data support the concept that many of the acute disease manifestations are mediated by IL-17, but further work is necessary to separate the distinct biological and clinical consequences of Th1-and Th17dependent disease components. A recent double-blind study exploring the therapeutic benefits of pulse glucocorticoids demonstrated that patients who received high doses of pulse steroids at the beginning of therapy had fewer disease flares and could discontinue therapy earlier. 6 Thus, inhibiting the Th17 arm of immunity may have long-lasting effects. One possible explanation is that IL-17 functions mainly as an inflammatory amplifier. Advancing from partial to more comprehensive disease control in GCA would require combining glucocorticoid therapy with Th1-targeted interventions. The most effective approach may be to inhibit Th1promoting cytokines, in particular IL-12. The tight correlation between blood and tissue T-cell subsets opens the door for blood-based biomarkers that can be used to closely follow the extent of T-cell and monocyte abnormalities and to appropriately tailor suppression of the multiple pathways driving this vasculitis.
